The present study provides more insightful knowledge of clinicopathological characteristics of TCC patients and emphasizes the role of BRAF mutation since the early stage of disease as putative predictive factor of response to targeted treatment in those patients with worse prognosis. The gene discussed is BRAF; the disease is tarsal-carpal coalition syndrome.